Phase 2 Prostate Cancer Trial, Recruiting (NCT06904313)

Phase 2 Prostate Cancer Trial, Recruiting NCT06904313 Sponsor: Akiva Mintz Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06904313 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older.
People who are able to give informed consent and follow the study procedures.
Women of childbearing potential must not be pregnant or breastfeeding, and a negative pregnancy test is required.

Who may not be able to join:

People whose total radiation exposure from research-related scans (including this study) has reached or exceeded the allowed annual limit of 50 mSv, as set by nuclear regulatory guidelines.
People who have already been enrolled in this same study more than four times.
People with severe claustrophobia, chronic pain, or bone and muscle conditions that would prevent them from completing the PET scan.
People currently receiving a type of treatment that targets a specific protein called PSMA (for example, a treatment called lutetium-177).
People who are pregnant or breastfeeding.
People who are not able to give informed consent.
People with any other condition that the trial doctor believes could affect their safety or the reliability of the study results (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 9732554955

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06904313

Sponsor: Akiva Mintz

Phase: Phase 2

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 9732554955

More information: https://clinicaltrials.gov/study/NCT06904313

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older.
People who are able to give informed consent and follow the study procedures.
Women of childbearing potential must not be pregnant or breastfeeding, and a negative pregnancy test is required.

Who may not be able to join:

People whose total radiation exposure from research-related scans (including this study) has reached or exceeded the allowed annual limit of 50 mSv, as set by nuclear regulatory guidelines.
People who have already been enrolled in this same study more than four times.
People with severe claustrophobia, chronic pain, or bone and muscle conditions that would prevent them from completing the PET scan.
People currently receiving a type of treatment that targets a specific protein called PSMA (for example, a treatment called lutetium-177).
People who are pregnant or breastfeeding.
People who are not able to give informed consent.
People with any other condition that the trial doctor believes could affect their safety or the reliability of the study results (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Akiva Mintz

Registry

ClinicalTrials.gov

Start date

12 May 2025

Est. completion

30 June 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Signal-to-Noise Ratio (SNR); Contrast-to-Noise Ratio (CNR); Coefficient of Variation (COV); Spatial Resolution (Full Width at Half Maximum - FWHM); Target-to-Background Ratio (TBR); Qualitative Image Quality Score (Likert Scale); Inter-reader Agreement (Weighted Kappa Statistics)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov